Navigation Links
NYSE Amex Accepts China Shenghuo's Compliance Plan for Continued Listing

KUNMING, China, June 8 /PRNewswire-Asia-FirstCall/ -- China Shenghuo Pharmaceutical Holdings, Inc. (NYSE Amex Equities: KUN) ("China Shenghuo" or the "Company"), which is engaged in the research, development, manufacture, and marketing of pharmaceutical, nutritional supplement and cosmetic products in the People's Republic of China ("PRC"), today announced that the NYSE Amex LLC (the "NYSE Amex" or "Exchange") has accepted the Company's plan of compliance for continued listing.

On February 10, 2009, the Company received notice from the NYSE Amex Staff indicating that the Company is below certain of the Exchange's continued listing standards due to the Company's failure to hold an annual meeting of stockholders in 2008, as set forth in Section 704 of the NYSE Amex Company Guide. The Company submitted a plan of compliance to the Exchange by February 17, 2009. The plan was accepted by the Exchange and a listing extension was granted until August 11, 2009. The Company will be subject to periodic review by Exchange Staff during the extension period. Failure to make progress consistent with the plan or to regain compliance with the continued listing standards by the end of the extension period could result in the Company being delisted from the Exchange.

The Company will hold its annual meeting of stockholders at 10:00 A.M. Beijing Time on Monday, June 15, 2009. The Company believes that holding the annual meeting will satisfy the deficiency, and the Company intends to hold future annual meetings of stockholders on an annual basis, in accordance with the Exchange's listing standards.

"We are pleased with the decision by the Exchange to continue our listing and look forward to meeting the business goals established by the Company in our plan," said Mr. Gui Hua Lan, Chief Executive Officer of China Shenghuo.

About China Shenghuo

Founded in 1995, China Shenghuo is a specialty pharmaceutical company that focuses on the research, development, manufacture and marketing of Sanchi-based medicinal and pharmaceutical, nutritional supplement and cosmetic products. Through its subsidiary, Kunming Shenghuo Pharmaceutical (Group) Co., Ltd., it owns thirty SFDA (State Food and Drug Administration) approved medicines, including the flagship product Xuesaitong Soft Capsules, which has already been listed in the Insurance Catalogue. At present, China Shenghuo incorporates a sales network of agencies and representatives throughout China, which markets Sanchi-based traditional Chinese medicine to hospitals and drug stores as prescription and OTC drugs primarily for the treatment of cardiovascular, cerebrovascular and peptic ulcer disease. The Company also exports medicinal products to Asian countries such as Indonesia, Singapore, Japan, Malaysia, and Thailand and to European countries such as the United Kingdom, Tajikstan, Russia and Kyrgyzstan. For more information, please visit .

Safe Harbor Statement

This press release may contain certain "forward-looking statements," as defined in the United States Private Securities Litigation Reform Act of 1995, that involve a number of risks and uncertainties. There can be no assurance that such statements will prove to be accurate, and the actual results and future events could differ materially from management's current expectations. Such factors include, but are not limited to, risks of litigation and governmental or other regulatory proceedings arising out of or related to any of the matters described in recent press releases, including arising out of the restatement of the Company's financial statements; the Company's ability to refinance or repay loans received; the Company's uncertain business condition; the Company's continuing ability to satisfy any requirements which may be prescribed by the Exchange for continued listing on the Exchange; risks arising from potential weaknesses or deficiencies in the Company's internal controls over financial reporting; the Company's reliance on one supplier for Sanchi; the possible effect of adverse publicity on the Company's business, including possible contract cancellation; the Company's ability to develop and market new products; the Company's ability to establish and maintain a strong brand; the Company's continued ability to obtain and maintain all certificates, permits and licenses required to open and operate retail specialty counters to offer its cosmetic products and conduct business in China; protection of the Company's intellectual property rights; market acceptance of the Company's products; changes in the laws of the People's Republic of China that affect the Company's operations; cost to the Company of complying with current and future governmental regulations; the impact of any changes in governmental regulations on the Company's operations; general economic conditions; and other factors detailed from time to time in the Company's filings with the United States Securities and Exchange Commission and other regulatory authorities. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

    For more information, please contact:

    China Shenghuo Pharmaceutical Holdings, Inc.
     Mr. Changhua Mu
     Securities Affairs Representative

     Eddie Cheung
     Investor Relations
     Tel:   +1-646-284-9414

SOURCE China Shenghuo Pharmaceutical Holdings, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. NYSE Amex LLC Accepts Plan of Compliance of The Quantum Group, Inc.
2. United States Patent and Trademark Office Accepts CoolTouch's Re-examination Request for Cynosure '873 Patent
3. NYSE Amex Accepts Interleukin Genetics Plan to Meet Continued Listing Standards
4. Gamma Pharmaceuticals Accepts PO From Leading St. Louis Missouri Distributor. Order Valued up to $850,000 Retail Market Value
5. FDA Accepts Nuvos Resubmission For Pennsaid(R)
6. ROXRO Announces FDA Accepts for Review NDA for ROX-888 for the Management of Acute Moderate to Severe Pain
7. Andre Konski, M.D., M.B.A., Accepts Radiation Oncology Position at Wayne State University and the Karmanos Cancer Institute
8. FDA Accepts Vanda Pharmaceuticals Iloperidone Resubmission and Sets New Action Date
9. FDA accepts Labopharms response for once-daily tramadol as complete Class 2 response
10. FDA Accepts Gentas NDA Amendment as Complete Response for Genasense(R) Treatment of Chronic Lymphocytic Leukemia
11. Partnering With MyPyramid: NUTRIKIDS Accepts the Challenge to Help Families Step Up to Healthier Living
Post Your Comments:
(Date:11/25/2015)... CA (PRWEB) , ... November 25, 2015 , ... According ... Vinci surgical robot is being more and more widely heralded as a breakthrough for ... da Vinci method has over traditional laparoscopic surgery is that it can greatly reduce ...
(Date:11/25/2015)... Boca Raton, Florida (PRWEB) , ... November 25, ... ... on-site diagnostic testing for physicians and athletic programs, launches new Wimbledon Athletics ... the importance of testing young athletes for unsuspected cardiac abnormalities. About 2,000 people ...
(Date:11/25/2015)... (PRWEB) , ... November 25, 2015 , ... ... a double board certified facial plastic surgeon specializing in both surgical and non-surgical ... of The Skin Spa at Hobgood Facial Plastic Surgery. , Highly trained ...
(Date:11/25/2015)... , ... November 25, 2015 , ... “While riding the ... inventor, from Bronx, N.Y. “I thought there had to be a convenient and comfortable ... PROTECTOR. , The PROTECTOR enables disabled individuals to safely travel during cold or inclement ...
(Date:11/25/2015)... ... 25, 2015 , ... "When I underwent breast reconstruction following ... uncomfortable," said an inventor from Bronx, N.Y. "In order to meet my own ... BRA for added comfort and support. The bra is easier to put on ...
Breaking Medicine News(10 mins):
(Date:11/25/2015)... , Nov. 25, 2015  Amgen (NASDAQ: ... License Application (BLA) with the United States ... ABP 501, a biosimilar candidate to Humira ® ... biosimilar application submitted to the FDA and represents Amgen,s ... Sean E. Harper , M.D., executive vice president ...
(Date:11/25/2015)... , Nov. 25, 2015  Linden Care, LLC, ... optimizing treatment outcomes for patients suffering from chronic pain, ... for a Temporary Restraining Order (TRO) enjoining Express Scripts ... two companies. --> --> ... all of its legal options. --> ...
(Date:11/25/2015)... 25, 2015 On Tuesday, November 24, ... trial against Wright Medical Technology, Inc. for product ... metal-on-metal hip implant device, awarded $11 million in ... week trial and three days of deliberations, the ... was defectively designed and unreasonably dangerous, and that ...
Breaking Medicine Technology: